Cardiovascular risk assessment for osteoporosis patients considering Romosozumab

IF 3.5 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Bone Pub Date : 2024-10-23 DOI:10.1016/j.bone.2024.117305

F. Macrae , E.M. Clark , K. Walsh , S.-J. Bailey , M. Roy , S. Hardcastle , C. Cockill , J.H. Tobias , B.G. Faber

引用次数: 0

Abstract

Cardiovascular risk scoaring tools are suitable for but not interchangable within the osteoporosis clinic.

查看原文本刊更多论文

对考虑使用 Romosozumab 的骨质疏松症患者进行心血管风险评估。

心血管风险评分工具适用于骨质疏松症诊所，但不能互换。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone 医学-内分泌学与代谢

CiteScore

8.90

自引率

4.90%

发文量

264

审稿时长

30 days

期刊介绍： BONE is an interdisciplinary forum for the rapid publication of original articles and reviews on basic, translational, and clinical aspects of bone and mineral metabolism. The Journal also encourages submissions related to interactions of bone with other organ systems, including cartilage, endocrine, muscle, fat, neural, vascular, gastrointestinal, hematopoietic, and immune systems. Particular attention is placed on the application of experimental studies to clinical practice.